Title
Caregiver willingness to give TPT to children living with drug-resistant TB patients
Date Issued
01 October 2022
Access level
open access
Resource Type
journal article
Author(s)
Rouzier V.
Murrill M.
Kim S.
Naini L.
Shenje J.
Mitchell E.
Raesi M.
Lourens M.
Mendoza A.
Conradie F.
Suryavanshi N.
Hughes M.
Shah S.
Churchyard G.
Swindells S.
Hesseling A.
Gupta A.
Publisher(s)
International Union Against Tuberculosis and Lung Disease
Abstract
BACKGROUND Pediatric household contacts (HHCs) of patients with multidrug-resistant TB (MDR-TB) are at high risk of infection and active disease. Evidence of caregiver willingness to give MDR-TB preventive therapy (TPT) to children is limited.METHODS This was a cross-sectional study of HHCs of patients with MDR-TB to assess caregiver willingness to give TPT to children aged <13 years.RESULTS Of 743 adult and adolescent HHCs, 299 reported caring for children aged <13 years of age. The median caregiver age was 35 years (IQR 27-48); 75% were women. Among caregivers, 89% were willing to give children MDR TPT. In unadjusted analyses, increased willingness was associated with TB-related knowledge (OR 5.1, 95% CI 2.3-11.3), belief that one can die of MDR-TB (OR 5.2, 95% CI 1.2-23.4), concern for MDR-TB transmission to child (OR 4.5, 95% CI 1.6-12.4), confidence in properly taking TPT (OR 4.5, 95% CI 1.6-12.6), comfort telling family about TPT (OR 5.5, 95% CI 2.1-14.3), and willingness to take TPT oneself (OR 35.1, 95% CI 11.0-112.8).CONCLUSIONS A high percentage of caregivers living with MDR- or rifampicin-resistant TB patients were willing to give children a hypothetical MDR TPT. These results provide important evidence for the potential uptake of effective MDR TPT when implemented.
Start page
949
End page
955
Volume
26
Issue
10
Language
English
OCDE Knowledge area
Enfermedades infecciosas
Subjects
Scopus EID
2-s2.0-85138662892
PubMed ID
Source
International Journal of Tuberculosis and Lung Disease
ISSN of the container
10273719
Sponsor(s)
This work was supported by the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH; Bethesda, MD, USA) [UM1AI068634, UM1AI068636, and UM1AI106701 to AIDS Clinical Trials Group]. Overall support for IMPAACT (International Maternal Pediatric Adolescent AIDS Clinical Trials Network) was provided by the NIAID, with co-funding from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) and the National Institute of Mental Health (NIMH) of NIH [UM1AI068632, UM1AI068616, UM1AI106716], and by NICHD contract number [HHSN275201800001I]. MTM received training support from the Johns Hopkins University Medical Scientist Training Program (Baltimore, MD, USA) funded by the National Institute of General Medical Sciences [5T32GM007309-43] as well as the UJMT Fogarty Global Health Fellowship [D43TW009340] funded by the Fogarty International Center; National Institute of Neurological Disorders and Stroke; National Heart, Lung and Blood Institute; and National Institute Environmental Health Sciences of the NIH. AG was supported by NIH/NIAID UM1 AI069465.
Sources of information:
Directorio de Producción Científica
Scopus